Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
15.00
-0.34 (-2.22%)
At close: Mar 25, 2026, 4:00 PM EDT
14.92
-0.08 (-0.53%)
Pre-market: Mar 26, 2026, 7:44 AM EDT
TNXP Employees
Tonix Pharmaceuticals Holding had 142 employees as of December 31, 2025. The number of employees increased by 61 or 75.31% compared to the previous year.
Employees
142
Change (1Y)
61
Growth (1Y)
75.31%
Revenue / Employee
$92,303
Profits / Employee
-$873,387
Market Cap
201.08M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 142 | 61 | 75.31% |
| Dec 31, 2024 | 81 | -22 | -21.36% |
| Dec 31, 2023 | 103 | -14 | -11.97% |
| Dec 31, 2022 | 117 | 44 | 60.27% |
| Dec 31, 2021 | 73 | 47 | 180.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| Alector | 103 |
| SAB Biotherapeutics | 86 |
| Keros Therapeutics | 78 |
| Rezolute | 75 |
| Cybin | 50 |
| Fennec Pharmaceuticals | 32 |
TNXP News
- 1 hour ago - Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - GlobeNewsWire
- 2 days ago - Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - GlobeNewsWire
- 7 days ago - Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - GlobeNewsWire
- 8 days ago - Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 8 days ago - Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum - Seeking Alpha
- 13 days ago - Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Benzinga
- 13 days ago - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 16 days ago - Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia - GlobeNewsWire